Muvalaplin: how it works, status and trials

Phase 3PillLowering lipoprotein(a)

Muvalaplin is an investigational daily pill that stops apo(a) from attaching to apoB, the first step in building lipoprotein(a). It is in phase 3 and is not approved.

In technical terms: Blocks the first binding step between apo(a) and apoB-100, so Lp(a) cannot assemble.

The highlighted badge marks where Muvalaplin acts. Open the full map or compare every therapy.

At a glance

Acts on: apo(a)–apoB-100 binding
How it is given: Oral small molecule · daily
What the main trial found: Lp(a) −86% (intact assay, 240 mg; KRAKEN)
Status (curated October 25, 2026): Phase 3

Where it fits in the body

Lipoprotein(a)

Lp(a) is an LDL-like particle with an extra protein, apo(a), made from the LPA gene. Its level is about 90% genetically determined. Antisense and siRNA drugs (16, 17) stop apo(a) production; muvalaplin (18) blocks apo(a) from attaching to apoB. Pelacarsen did not meet its primary outcome; other outcome trials are ongoing.

See it on the interactive map

Trials and registry status

From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.

Muvalaplin from Eli Lilly

Stage: Phase 3. 1 active of 6 registered trials. 5 new papers in the last 31 days.

MOVE-Lp(a) (NCT07157774): recruiting, primary completion 2031-03

Evidence

KRAKEN (PubMed 39556768)

Common questions

How does Muvalaplin work?

Muvalaplin is an investigational daily pill that stops apo(a) from attaching to apoB, the first step in building lipoprotein(a). It is in phase 3 and is not approved. In technical terms: Blocks the first binding step between apo(a) and apoB-100, so Lp(a) cannot assemble. It acts on apo(a)–apoB-100 binding.

How much does Muvalaplin lower cholesterol or other lipids?

Lp(a) −86% (intact assay, 240 mg; KRAKEN). Individual results differ, and a clinician can say what to expect for one person.

Is Muvalaplin approved, and what is the status?

Phase 3 (curated October 25, 2026). Registry stage as of October 27, 2026: Muvalaplin, Phase 3.

How is Muvalaplin taken?

Oral small molecule · daily.

Related therapies

Pelacarsen: Phase 3 (outcome trial negative)
Olpasiran, lepodisiran and zerlasiran: Olpasiran, lepodisiran phase 3 outcome trials; zerlasiran phase 2

Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.